With a bold strategic acquisition, this commercial-stage company has taken a transformative leap - broadening its revenue base with synergistic assets and positioning itself for sustained, long-term growth.
The company we are profiling today is CorMedix Inc. (CRMD), whose lead product is DefenCath, indicated for the prevention of catheter-related bloodstream infections in patients undergoing hemodialysis through a central venous catheter.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com